If you experience heavy periods whilst taking Ozempic, it is essential to consult your GP to exclude other important causes and determine appropriate management
But what, exactly, is the difference, and why might you choose one over the other
7 A meta-analysis of outcomes data from completed cardiovascular outcome trials suggests that, apart from saxagliptin, DPP-4 inhibitors have a neutral effect on the risk of cardiovascular death, myocardial infarction, stroke and hospitalisation for heart failure
Theyre FDA-approved for people with a clinical need: A BMI of 30 or higher (obesity), or A BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea Your doctor will also consider your full health history thyroid conditions, eating disorders, pancreatitis history, and current medications all factor into whether a GLP-1 is appropriate
Too often, women are told these symptoms are just part of aging or are offered quick fixes that miss the root cause
ERDERA, the European Rare Diseases Research Alliance, will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026
